A Phase 1 interventional study of Midazolam Syrup and Midazolam Solution in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-24.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to assess the effect of Pirtobrutinib (LOXO-305) on how fast different formulations of midazolam gets into the blood stream and how long it takes the body to remove it when administered in healthy participants. The study will also access how much endogenous coproporphyrins I and III as biomarkers of OATP1B1 and OATP1B3 is in the bloodstream and how the body handles and eliminates them following single and multiple oral doses of Pirtobrutinib. Safety and tolerability of Pirtobrutinib will also be evaluated. For each participant, the total duration of the study will be 59 days, including screening.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A single IV bolus dose of midazolam will be administered in the morning following a 10-hour fast prior to dosing and a 4-hour fast postdose on Day 1 and Day 15.
Drug: Midazolam Solution
A single oral dose of midazolam will be administered in the morning following a 10-hour fast prior to dosing and a 4-hour fast postdose on Day 3 and Day 17.
Drug: Midazolam Syrup
Multiple oral doses of Pirtobrutinib once a day (QD) will be administered on Days 5 through Day 17.
Drug: Pirtobrutinib
Administered Orally.
Administered IV bolus.
Administered Orally.
Also known as: LOXO-305, LY3527727
Pharmacokinetics (PK): Area Under the Concentration-Time Curve From Hour 0 to the Last Measurable Concentration (AUC0-t) of Midazolam and Its Metabolite 1-hydroxymidazolam (1-OH-midazolam) Following Oral Dose Administration
PK: AUC0-t of midazolam and its metabolite 1-OH-midazolam following oral dose administration was reported.
Time frame: Period 1: Day 3 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 17 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)
PK: Area Under the Concentration-Time From Time 0 Extrapolated To Infinity (AUC0-inf) of Midazolam and Its Metabolite 1-OH-Midazolam Following Oral Dose Administration
PK: AUC(0-inf) of midazolam and its metabolite 1-OH-midazolam following oral dose administration was reported.
Time frame: Period 1: Day 3 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 17 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)
PK: Percentage Extrapolation for AUC0-inf (%AUCextrap) of Midazolam and Its Metabolite 1-OH-Midazolam Following Oral Dose Administration
PK: %AUCextrap of midazolam and its metabolite 1-OH-midazolam following oral dose administration was reported.
Time frame: Period 1: Day 3 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 17 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)
PK: Maximum Observed Plasma Concentration (Cmax) of Midazolam and Its Metabolite 1-OH-Midazolam Following Oral Dose Administration
PK: Cmax of midazolam and its metabolite 1-OH-midazolam following oral dose administration was reported.
Time frame: Period 1: Day 3 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 17 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)
PK: Time to Maximum Observed Plasma Concentration (Tmax) of Midazolam and Its Metabolite 1-OH-Midazolam Following Oral Dose Administration
PK: tmax of midazolam and its metabolite 1-OH-midazolam following oral dose administration was reported.
Time frame: Period 1: Day 3 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 17 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)
PK: Apparent Terminal Elimination Rate Constant (Lambda [λ] z) of Midazolam and Its Metabolite 1-OH-Midazolam Following Oral Dose Administration
PK: λz of midazolam and its metabolite 1-OH-midazolam following oral dose administration was reported.
Time frame: Period 1: Day 3 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 17 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)
PK: Apparent Systemic Clearance (CL/F) of Midazolam Following Oral Dose Administration
PK: CL/F of midazolam following oral dose administration was reported.
Time frame: Period 1: Day 3 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 17 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)
PK: Apparent Volume of Distribution (Vz/F) of Midazolam Following Oral Dose Administration
PK: Vz/F of midazolam following oral dose administration was reported.
Time frame: Period 1: Day 3 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 17 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)
PK: Apparent Plasma Terminal Elimination Half-life (t½) of Midazolam and Its Metabolite 1-OH-Midazolam Following Oral Dose Administration
PK: t½ of midazolam and its metabolite 1-OH-midazolam following oral dose administration was reported.
Time frame: Period 1: Day 3 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 17 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)
PK: Total Clearance (CL) of Midazolam Following Intravenous Dose Administration
PK: CL of midazolam following intravenous dose administration was reported.
Time frame: Period 1: Day 1 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 15 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)
PK: Volume of Distribution (Vz) of Midazolam Following Intravenous Dose Administration
PK: Vz of midazolam following intravenous dose administration was reported.
Time frame: Period 1: Day 1 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 15 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)
PK: Volume of Distribution at Steady State (Vss) of Midazolam Following Intravenous Dose Administration
PK: Vss of midazolam following intravenous dose administration was reported.
Time frame: Period 1: Day 1 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 15 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)
PK: Area Under the Concentration-Time Curve From Hour 0 to the Last Measurable Concentration (AUC0-t) of Midazolam and Its Metabolite 1-OH-midazolam Following Intravenous Dose Administration
PK: AUC0-t of midazolam and its metabolite 1-OH-midazolam following intravenous dose administration was reported.
Time frame: Period 1: Day 1 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 15 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)
PK: Area Under the Concentration-Time From Time 0 Extrapolated To Infinity (AUC0-inf) of Midazolam and Its Metabolite 1-OH-midazolam Following Intravenous Dose Administration
PK: AUC0-inf of midazolam and its metabolite 1-OH-midazolam following intravenous dose administration was reported.
Time frame: Period 1: Day 1 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 15 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)
PK: Percentage Extrapolation for AUC0-inf (%AUCextrap) of Midazolam and Its Metabolite 1-OH-midazolam Following Intravenous Dose Administration
PK: %AUCextrap of midazolam and its metabolite 1-OH-midazolam following intravenous dose administration was reported.
Time frame: Period 1: Day 1 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 15 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)
PK: Maximum Observed Plasma Concentration (Cmax) of Midazolam and Its Metabolite 1-OH-midazolam Following Intravenous Dose Administration
PK: Cmax of midazolam and its metabolite 1-OH-midazolam following intravenous dose administration was reported.
Time frame: Period 1: Day 1 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 15 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)
PK: Time to Maximum Observed Plasma Concentration (Tmax) of Midazolam and Its Metabolite 1-OH-midazolam Following Intravenous Dose Administration
PK: tmax of midazolam and its metabolite 1-OH-midazolam following intravenous dose administration was reported.
Time frame: Period 1: Day 1 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 15 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)
PK: Apparent Terminal Elimination Rate Constant (λz) of Midazolam and Its Metabolite 1-OH-midazolam Following Intravenous Dose Administration
PK: λz of midazolam and its metabolite 1-OH-midazolam following intravenous dose administration was reported.
Time frame: Period 1: Day 1 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 15 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)
PK: Apparent Plasma Terminal Elimination Half-life (t½) of Midazolam and Its Metabolite 1-OH-midazolam Following Intravenous Dose Administration
PK: t1/2 of midazolam and its metabolite 1-OH-midazolam following intravenous dose administration was reported.
Time frame: Period 1: Day 1 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose); Period 2: Day 15 (pre-dose, 5 minutes, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours post-dose)
PK: Area Under the Concentration-Time Curve From Hour 0 to the Last Measurable Concentration (AUC0-t) of Pirtobrutinib
PK: AUC0-t of Pirtobrutinib was reported.
Time frame: Period 2: Day 5, Day 14 and Day 15 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours post-dose), Day 17 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 100 hours post-dose)
PK: Area Under the Concentration-time Curve During a Dosing Interval (AUCtau) of Pirtobrutinib
PK: AUCtau of Pirtobrutinib was reported.
Time frame: Period 2: Day 5, Day 14 and Day 15 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours post-dose), Day 17 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 100 hours post-dose)
PK: Maximum Observed Plasma Concentration (Cmax) of Pirtobrutinib
PK: Cmax of Pirtobrutinib was reported.
Time frame: Period 2: Day 5, Day 14 and Day 15 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours post-dose), Day 17 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 100 hours post-dose)
PK: Concentration Observed at the End Of the Dosing Interval (Ctrough) of Pirtobrutinib
PK: Ctrough of Pirtobrutinib before multiple oral doses administration was reported.
Time frame: Period 2: 24-hour post-dose on Day 14, Day 15, and Day 17
PK: Time To Maximum Observed Plasma Concentration (Tmax) of Pirtobrutinib
PK: tmax of Pirtobrutinib was reported.
Time frame: Period 2: Day 5, Day 14 and Day 15 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours post-dose), Day 17 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 100 hours post-dose)
PK: Apparent Systemic Plasma Clearance at Steady State (CL,ss/F) of Pirtobrutinib
PK: CL,ss/F of Pirtobrutinib was reported.
Time frame: Period 2: Day 14 and Day 15 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours post-dose), Day 17 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 100 hours post-dose)
PK: Accumulation Ratio (RAUC) of Pirtobrutinib
RAUC was ratio of Day 14 AUCtau to Day 5 AUCtau.
Time frame: Period 2: Day 5 and Day 14 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours post-dose)
| Milestone | Period 1: All Participants: Midazolam (IV + Oral Dose) | Period 2: All Participants: Pirtobrutinib + Midazolam (IV + Oral Dose) |
|---|---|---|
| Started | 15 | 0 |
| Received at least 1 dose of study drug | 15 | 0 |
| Completed | 15 | 0 |
| Not completed | 0 | 0 |
| Milestone | Period 1: All Participants: Midazolam (IV + Oral Dose) | Period 2: All Participants: Pirtobrutinib + Midazolam (IV + Oral Dose) |
|---|---|---|
| Started | 0 | 15 |
| Received at least 1 dose of study drug | 0 | 15 |
| Completed | 0 | 15 |
| Not completed | 0 | 0 |
PK: AUC0-t of midazolam and its metabolite 1-OH-midazolam following oral dose administration was reported.
| Hours*nanograms per milliliter (h*ng/mL) | Period 1: Oral Midazolam 500 mcg (Day 3) | Period 2: Pirtobrutinib 200 mg + Oral Midazolam 500 mcg (Day 17) |
|---|---|---|
| Midazolam | 4.81 ± 40.8 | 8.30 ± 43.2 |
| Metabolite: 1-OH-medazolam | 2.24 ± 41.9 | 2.52 ± 40.6 |
PK: AUC(0-inf) of midazolam and its metabolite 1-OH-midazolam following oral dose administration was reported.
| h*ng/mL | Period 1: Oral Midazolam 500 mcg (Day 3) | Period 2: Pirtobrutinib 200 mg + Oral Midazolam 500 mcg (Day 17) |
|---|---|---|
| Midazolam | 5.31 ± 43.1 | 9.01 ± 44.0 |
| Metabolite: 1-OH-midazolam | 2.60 ± 39.9 | 2.92 ± 42.2 |
PK: %AUCextrap of midazolam and its metabolite 1-OH-midazolam following oral dose administration was reported.
| percentage of AUC0-inf | Period 1: Oral Midazolam 500 mcg (Day 3) | Period 2: Pirtobrutinib 200 mg + Oral Midazolam 500 mcg (Day 17) |
|---|---|---|
| Midazolam | 8.84 ± 33.7 | 7.42 ± 35.3 |
| Metabolite: 1-OH-midazolam | 12.9 ± 37.5 | 12.2 ± 48.6 |
PK: Cmax of midazolam and its metabolite 1-OH-midazolam following oral dose administration was reported.
| nanograms per milliliter (ng/mL) | Period 1: Oral Midazolam 500 mcg (Day 3) | Period 2: Pirtobrutinib 200 mg + Oral Midazolam 500 mcg (Day 17) |
|---|---|---|
| Midazolam | 2.33 ± 36.7 | 3.68 ± 34.3 |
| Metabolite: 1-OH-midazolam | 1.25 ± 42.2 | 1.41 ± 40.2 |
PK: tmax of midazolam and its metabolite 1-OH-midazolam following oral dose administration was reported.
| Hours | Period 1: Oral Midazolam 500 mcg (Day 3) | Period 2: Pirtobrutinib 200 mg + Oral Midazolam 500 mcg (Day 17) |
|---|---|---|
| Midazolam | 0.750 (0.500 to 1.00) | 0.500 (0.500 to 0.750) |
| Metabolite: 1-OH-midazolam | 0.750 (0.500 to 1.00) | 0.500 (0.500 to 1.00) |
PK: λz of midazolam and its metabolite 1-OH-midazolam following oral dose administration was reported.
| one per hour (1/h) | Period 1: Oral Midazolam 500 mcg (Day 3) | Period 2: Pirtobrutinib 200 mg + Oral Midazolam 500 mcg (Day 17) |
|---|---|---|
| Midazolam | 0.316 ± 50.7 | 0.227 ± 50.2 |
| Metabolite: 1-OH-midazolam | 0.441 ± 35.4 | 0.419 ± 61.2 |
PK: CL/F of midazolam following oral dose administration was reported.
| Liters per hour (L/h) | Period 1: Oral Midazolam 500 mcg (Day 3) | Period 2: Pirtobrutinib 200 mg + Oral Midazolam 500 mcg (Day 17) |
|---|---|---|
| PK: Apparent Systemic Clearance (CL/F) of Midazolam Following Oral Dose Administration | 94.2 ± 43.1 | 55.5 ± 44.0 |
PK: Vz/F of midazolam following oral dose administration was reported.
| Liters | Period 1: Oral Midazolam 500 mcg (Day 3) | Period 2: Pirtobrutinib 200 mg + Oral Midazolam 500 mcg (Day 17) |
|---|---|---|
| PK: Apparent Volume of Distribution (Vz/F) of Midazolam Following Oral Dose Administration | 298 ± 29.7 | 244 ± 29.6 |
PK: t½ of midazolam and its metabolite 1-OH-midazolam following oral dose administration was reported.
| hours | Period 1: Oral Midazolam 500 mcg (Day 3) | Period 2: Pirtobrutinib 200 mg + Oral Midazolam 500 mcg (Day 17) |
|---|---|---|
| Midazolam | 2.20 ± 50.7 | 3.05 ± 50.2 |
| Metabolite: 1-OH-midazolam | 1.57 ± 35.4 | 1.65 ± 61.2 |
PK: CL of midazolam following intravenous dose administration was reported.
| L/h | Period 1: IV Midazolam 250 mcg (Day 1) | Period 2: Pirtobrutinib 200 mg + IV Midazolam 250 mcg (Day 15) |
|---|---|---|
| PK: Total Clearance (CL) of Midazolam Following Intravenous Dose Administration | 26.0 ± 21.4 | 23.1 ± 26.5 |
PK: Vz of midazolam following intravenous dose administration was reported.
| Liters | Period 1: IV Midazolam 250 mcg (Day 1) | Period 2: Pirtobrutinib 200 mg + IV Midazolam 250 mcg (Day 15) |
|---|---|---|
| PK: Volume of Distribution (Vz) of Midazolam Following Intravenous Dose Administration | 113 ± 34.2 | 105 ± 37.8 |
PK: Vss of midazolam following intravenous dose administration was reported.
| Liters | Period 1: IV Midazolam 250 mcg (Day 1) | Period 2: Pirtobrutinib 200 mg + IV Midazolam 250 mcg (Day 15) |
|---|---|---|
| PK: Volume of Distribution at Steady State (Vss) of Midazolam Following Intravenous Dose Administration | 78.2 ± 29.4 | 76.1 ± 31.0 |
PK: AUC0-t of midazolam and its metabolite 1-OH-midazolam following intravenous dose administration was reported.
| h*ng/mL | Period 1: IV Midazolam 250 mcg (Day 1) | Period 2: Pirtobrutinib 200 mg + IV Midazolam 250 mcg (Day 15) |
|---|---|---|
| Midazolam | 8.89 ± 21.6 | 10.1 ± 25.1 |
| Metabolite: 1-OH-medazolam | 1.39 ± 41.7 | 1.21 ± 35.7 |
PK: AUC0-inf of midazolam and its metabolite 1-OH-midazolam following intravenous dose administration was reported.
| h*ng/mL | Period 1: IV Midazolam 250 mcg (Day 1) | Period 2: Pirtobrutinib 200 mg + IV Midazolam 250 mcg (Day 15) |
|---|---|---|
| Midazolam | 9.62 ± 21.4 | 10.8 ± 26.5 |
| Metabolite: 1-OH-medazolam | 2.13 ± 43.0 | 1.62 ± 25.2 |
PK: %AUCextrap of midazolam and its metabolite 1-OH-midazolam following intravenous dose administration was reported.
| percentage of AUC0-inf | Period 1: IV Midazolam 250 mcg (Day 1) | Period 2: Pirtobrutinib 200 mg + IV Midazolam 250 mcg (Day 15) |
|---|---|---|
| Midazolam | 7.13 ± 37.1 | 6.44 ± 42.0 |
| Metabolite: 1-OH-medazolam | 19.6 ± 24.7 | 24.7 ± 11.5 |
PK: Cmax of midazolam and its metabolite 1-OH-midazolam following intravenous dose administration was reported.
| ng/mL | Period 1: IV Midazolam 250 mcg (Day 1) | Period 2: Pirtobrutinib 200 mg + IV Midazolam 250 mcg (Day 15) |
|---|---|---|
| Midazolam | 6.96 ± 34.8 | 6.91 ± 27.8 |
| Metabolite: 1-OH-medazolam | 0.512 ± 31.7 | 0.475 ± 28.6 |
PK: tmax of midazolam and its metabolite 1-OH-midazolam following intravenous dose administration was reported.
| hours | Period 1: IV Midazolam 250 mcg (Day 1) | Period 2: Pirtobrutinib 200 mg + IV Midazolam 250 mcg (Day 15) |
|---|---|---|
| Midazolam | 0.0833 (0.0833 to 0.250) | 0.0833 (0.0833 to 0.0833) |
| Metabolite: 1-OH-medazolam | 0.750 (0.500 to 1.00) | 0.750 (0.500 to 1.00) |
PK: λz of midazolam and its metabolite 1-OH-midazolam following intravenous dose administration was reported.
| 1/h | Period 1: IV Midazolam 250 mcg (Day 1) | Period 2: Pirtobrutinib 200 mg + IV Midazolam 250 mcg (Day 15) |
|---|---|---|
| Midazolam | 0.229 ± 37.0 | 0.221 ± 49.5 |
| Metabolite: 1-OH-medazolam | 0.224 ± 55.7 | 0.282 ± 47.8 |
PK: t1/2 of midazolam and its metabolite 1-OH-midazolam following intravenous dose administration was reported.
| hours | Period 1: IV Midazolam 250 mcg (Day 1) | Period 2: Pirtobrutinib 200 mg + IV Midazolam 250 mcg (Day 15) |
|---|---|---|
| Midazolam | 3.02 ± 37.0 | 3.13 ± 49.5 |
| Metabolite: 1-OH-medazolam | 3.09 ± 55.7 | 2.46 ± 47.8 |
PK: AUC0-t of Pirtobrutinib was reported.
| h*ng/mL | Period 2: Pirtobrutinib 200 mg (Day 5) | Period 2: Pirtobrutinib 200 mg (Day 14) | Period 2: Pirtobrutinib 200 mg + IV Midazolam 250 mcg (Day 15) | Period 2: Pirtobrutinib 200 mg + Oral Midazolam 500 mcg (Day 17) |
|---|---|---|---|---|
| PK: Area Under the Concentration-Time Curve From Hour 0 to the Last Measurable Concentration (AUC0-t) of Pirtobrutinib | 54800 ± 20.0 | 114000 ± 26.0 | 115000 ± 25.0 | 211000 ± 33.8 |
PK: AUCtau of Pirtobrutinib was reported.
| h*ng/mL | Period 2: Pirtobrutinib 200 mg (Day 5) | Period 2: Pirtobrutinib 200 mg (Day 14) | Period 2: Pirtobrutinib 200 mg + IV Midazolam 250 mcg (Day 15) | Period 2: Pirtobrutinib 200 mg + Oral Midazolam 500 mcg (Day 17) |
|---|---|---|---|---|
| PK: Area Under the Concentration-time Curve During a Dosing Interval (AUCtau) of Pirtobrutinib | 55000 ± 20.0 | 114000 ± 26.1 | 116000 ± 25.0 | 118000 ± 25.5 |
PK: Cmax of Pirtobrutinib was reported.
| ng/mL | Period 2: Pirtobrutinib 200 mg (Day 5) | Period 2: Pirtobrutinib 200 mg (Day 14) | Period 2: Pirtobrutinib 200 mg + IV Midazolam 250 mcg (Day 15) | Period 2: Pirtobrutinib 200 mg + Oral Midazolam 500 mcg (Day 17) |
|---|---|---|---|---|
| PK: Maximum Observed Plasma Concentration (Cmax) of Pirtobrutinib | 4880 ± 18.5 | 8120 ± 27.1 | 8620 ± 23.1 | 8750 ± 27.2 |
PK: Ctrough of Pirtobrutinib before multiple oral doses administration was reported.
| ng/mL | Period 2: Pirtobrutinib 200 mg (Day 14) | Period 2: Pirtobrutinib 200 mg + IV Midazolam 250 mcg (Day 15) | Period 2: Pirtobrutinib 200 mg + Oral Midazolam 500 mcg (Day 17) |
|---|---|---|---|
| PK: Concentration Observed at the End Of the Dosing Interval (Ctrough) of Pirtobrutinib | 3060 ± 32.1 | 3180 ± 36.4 | 3050 ± 32.7 |
PK: tmax of Pirtobrutinib was reported.
| hours | Period 2: Pirtobrutinib 200 mg (Day 5) | Period 2: Pirtobrutinib 200 mg (Day 14) | Period 2: Pirtobrutinib 200 mg + IV Midazolam 250 mcg (Day 15) | Period 2: Pirtobrutinib 200 mg + Oral Midazolam 500 mcg (Day 17) |
|---|---|---|---|---|
| PK: Time To Maximum Observed Plasma Concentration (Tmax) of Pirtobrutinib | 2.50 (1.00 to 4.00) | 3.00 (2.00 to 4.00) | 3.00 (0.750 to 6.00) | 3.00 (1.00 to 4.00) |
PK: CL,ss/F of Pirtobrutinib was reported.
| L/h | Period 2: Pirtobrutinib 200 mg (Day 14) | Period 2: Pirtobrutinib 200 mg + IV Midazolam 250 mcg (Day 15) | Period 2: Pirtobrutinib 200 mg + Oral Midazolam 500 mcg (Day 17) |
|---|---|---|---|
| PK: Apparent Systemic Plasma Clearance at Steady State (CL,ss/F) of Pirtobrutinib | 1.75 ± 26.1 | 1.72 ± 25.0 | 1.69 ± 25.5 |
RAUC was ratio of Day 14 AUCtau to Day 5 AUCtau.
| Ratio | Period 2: Pirtobrutinib 200 mg |
|---|---|
| PK: Accumulation Ratio (RAUC) of Pirtobrutinib | 2.08 ± 15.9 |
Collected over From Day 1 up to 7 days post end of treatment (i.e., up to Day 30). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Period 1: IV Midazolam 250 mcg | 0/15 (0%) | 0/15 (0%) | 1/15 (6.7%) |
| Period 1: Oral Midazolam 500 mcg | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) |
| Period 2: Pirtobrutinib 200 mg | 0/15 (0%) | 0/15 (0%) | 3/15 (20%) |
| Period 2: Pirtobrutinib 200 mg + IV Midazolam 250 mcg | 0/15 (0%) | 0/15 (0%) | 1/15 (6.7%) |
| Period 2: Pirtobrutinib 200 mg + Oral Midazolam 500 mcg | 0/15 (0%) | 0/15 (0%) | 0/15 (0%) |
| Event | Period 1: IV Midazolam 250 mcg | Period 1: Oral Midazolam 500 mcg | Period 2: Pirtobrutinib 200 mg | Period 2: Pirtobrutinib 200 mg + IV Midazolam 250 mcg | Period 2: Pirtobrutinib 200 mg + Oral Midazolam 500 mcg |
|---|---|---|---|---|---|
| ConstipationGastrointestinal disorders | 0/15 | 0/15 | 1/15 | 0/15 | 0/15 |
| FlatulenceGastrointestinal disorders | 0/15 | 0/15 | 1/15 | 0/15 | 0/15 |
| Injection site painGeneral disorders | 1/15 | 0/15 | 0/15 | 0/15 | 0/15 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/15 | 0/15 | 0/15 | 1/15 | 0/15 |
| PollakiuriaRenal and urinary disorders | 0/15 | 0/15 | 1/15 | 0/15 | 0/15 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 0/15 | 0/15 | 1/15 | 0/15 | 0/15 |
| RashSkin and subcutaneous tissue disorders | 0/15 | 0/15 | 1/15 | 0/15 | 0/15 |
All participants who received at least 1 dose of study drug.
| Age, Continuous(years) | All Participants: Midazolam (IV + Oral Dose) + Pirtobrutinib |
|---|---|
| Mean | 33.9 ± 9.50 |
| Sex: Female, Male(Participants) | All Participants: Midazolam (IV + Oral Dose) + Pirtobrutinib |
|---|---|
| Female | 3 |
| Male | 12 |
| Ethnicity (NIH/OMB)(Participants) | All Participants: Midazolam (IV + Oral Dose) + Pirtobrutinib |
|---|---|
| Hispanic or Latino | 7 |
| Not Hispanic or Latino | 8 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | All Participants: Midazolam (IV + Oral Dose) + Pirtobrutinib |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 3 |
| White | 10 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
| Region of Enrollment(Participants) | All Participants: Midazolam (IV + Oral Dose) + Pirtobrutinib |
|---|---|
| United States | 15 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2020 to primary completion in Oct 2020, 1 month.
Results were first posted in Feb 2025, 4 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Midazolam · Pirtobrutinib